featured
GS-9674 Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Hepatology (Baltimore, Md.)
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis
Hepatology 2019 Sep 01;70(3)788-801, M Trauner, A Gulamhusein, B Hameed, S Caldwell, ML Shiffman, C Landis, B Eksteen, K Agarwal, A Muir, S Rushbrook, X Lu, J Xu, JC Chuang, AN Billin, G Li, C Chung, GM Subramanian, RP Myers, CL Bowlus, KV KowdleyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.